An observational study in Superficial Femoral Artery Stenosis, Iliac Artery Stenosis and Popliteal Artery Stenosis, sponsored by Cordis US Corp.. Not yet recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-14.
Sponsored by Cordis US Corp. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Constriction, Pathologic with a site in Spain — 1 open to participants now, 4 under way, none of them phase 3. Constriction, Pathologic · Spain.
Among the 13 studies in Constriction, Pathologic with a site in Spain, this one is the only one that started in 2026, is one of 7 observational ones, and was the 13th registered.
457 studies on the registry are indexed under Constriction, Pathologic; 110 are open to participants now.
Browse Constriction, Pathologic studies →1 of the 13 studies in Constriction, Pathologic with a site in Spain is open now.
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 67 Constriction, Pathologic studies recruiting now, 34 (51%) set no upper age limit and 14 (21%) stop at 75 or younger; 8 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 240 is above the median of 84 across 144 observational studies indexed under Constriction, Pathologic.
Median enrollment 116 across the 6 interventional studies, 94 across the 7 observational. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 13 have an industry lead sponsor. The 10 most frequent:
This study is registered under Cordis US Corp., one of the names counted as Cordis Corporation. Under that name alone:
Cordis US Corp. is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Cordis Corporation has 1 study filed under Constriction, Pathologic — fewer than ten, so there is no comparison to draw.
1 of the studies in Constriction, Pathologic with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05149755Medtronic CardiovascularEvolut™ EXPAND TAVR II Pivotal Trial | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Constriction, Pathologic with a site in Spain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate long-term safety and performance per the intended use of the S.M.A.R.T.™ Nitinol Stent System (SMART 120/150), S.M.A.R.T.™ CONTROL™ Nitinol Stent System (SMART CONTROL) and S.M.A.R.T.™ Flex Vascular Stent System (SMART Flex) in the treatment of iliac and femoropopliteal artery disease.
The REAL-SMART study is a multi-center, non-randomized, observational analysis of retrospective data collected on all subjects treated with SMART 120/150, SMART CONTROL or SMART Flex. The purpose of this study is to evaluate long-term safety and performance per the intended use of the three (3) study devices. Each device constitutes a separate study arm and each arm is further stratified by indication, of which there are two per device. The study is conducted in approximately 20 sites located in approximately three (3) European countries with high volume use of one or more of the study devices. The enrollment and data collection take approximately 6-8 months.
Subjects to be included in this study are those treated with SMART 120/150, SMART CONTROL or SMART Flex, according to the respective Instructions for Use, for stenosis in the iliac, superficial femoral and/or proximal popliteal arteries. Approximately 20 sites located in approximately three (3) European countries with high volume use of one or more of the study products will participate.
Inclusion Criteria: For data mining purposes, the following criteria will apply in determining which subjects to include in the study:
It is recommended to include subjects with follow-up data available for a minimum of five (5) years from the date of treatment/procedure or until time of death, whichever came first. Subjects not included because follow-up information is unavailable will be documented, wherever possible, with respect to demographics and presenting disease state to determine whether they are similar to subjects with follow-up that are enrolled.
Exclusion Criteria: For data mining purposes, the following criteria will apply in determining which subjects to exclude in the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The Cordis S.M.A.R.T.TM Nitinol Stent System (SMART 120/150) is indicated in enabling treatment in patients with atherosclerotic disease of the superficial femoral artery (SFA).
Device: S.M.A.R.T.™ Nitinol Stent System (SMART 120/150)
The Cordis S.M.A.R.T.TM Nitinol Stent System (SMART 120/150) is indicated in enabling treatment in patients with atherosclerotic disease of the proximal popliteal artery (PPA).
Device: S.M.A.R.T.™ Nitinol Stent System (SMART 120/150)
The Cordis S.M.A.R.T.TM CONTROLTM Nitinol Stent System is indicated in enabling treatment in patients with atherosclerotic disease of the iliac artery.
Device: S.M.A.R.T.™ CONTROL ™ Nitinol Stent System
The Cordis S.M.A.R.T.TM CONTROLTM Nitinol Stent System is indicated in enabling treatment in patients with atherosclerotic disease of the superficial femoral artery (SFA).
Device: S.M.A.R.T.™ CONTROL ™ Nitinol Stent System
The Cordis S.M.A.R.T.TM Flex Stent is indicated in enabling treatment of patients with symptomatic vascular stenotic and/or occlusive diseases in the superficial femoral artery (SFA).
Device: S.M.A.R.T.™ Flex Vascular Stent System
The Cordis S.M.A.R.T.TM Flex Stent is indicated in enabling treatment of patients with symptomatic vascular stenotic and/or occlusive diseases in the proximal popliteal artery (PPA).
Device: S.M.A.R.T.™ Flex Vascular Stent System
The Cordis S.M.A.R.T.™ Nitinol Stent System is intended to deliver a self-expanding endovascular stent to the peripheral vasculature via a sheathed delivery system. The stent component imparts an outward radial force on the luminal surface of the vessel wall restoring vascular patency. The S.M.A.R.T. ™ Nitinol Stent System is indicated in enabling treatment in patients with atherosclerotic disease of the superficial femoral artery and proximal popliteal artery.
The Cordis S.M.A.R.T.™ CONTROL™ Nitinol Stent System is intended to deliver a self-expanding endovascular stent to the iliac and/or superficial femoral arteries via a sheathed delivery system. The stent component imparts an outward radial force on the luminal surface of the vessel wall restoring vascular patency. The S.M.A.R.T. ™ CONTROL™ Nitinol Stent System is indicated in enabling treatment in patients with atherosclerotic disease of iliac and/or superficial femoral arteries.
The Cordis S.M.A.R.T.™ Flex Stent is a single-use device consisting of an endovascular stent and sheath delivery system, intended to deliver a self-expanding endovascular stent to the superficial femoral artery (SFA). The stent component imparts an outward radial force on the luminal surface of the vessel wall restoring vascular patency. The S.M.A.R.T.™ Flex Stent is indicated in enabling treatment of patients with symptomatic vascular stenotic and/or occlusive diseases in the superficial femoral artery and proximal popliteal artery.
Technical success of SMART 120/150 in patients with obstructive SFA disease
Technical success, defined as achievement of a final diameter stenosis of less than or equal to (≤) 30% residual stenosis at the conclusion of the index procedure
Time frame: At the conclusion of the index procedure
Major amputation in patients treated with SMART 120/150 for obstructive SFA disease
Major amputation at 12 months post-index procedure
Time frame: At 12 months post-index procedure
Technical success of SMART 120/150 in patients with obstructive PPA disease
Technical success, defined as achievement of a final diameter stenosis of less than or equal to (≤) 30% residual stenosis at the conclusion of the index procedure
Time frame: At the conclusion of the index procedure
Major amputation in patients treated with SMART 120/150 for obstructive PPA disease
Major amputation at 12 months post-index procedure
Time frame: At 12 months post-index procedure
Technical success of SMART CONTROL in patients with obstructive iliac artery disease
Technical success, defined as achievement of a final diameter stenosis of less than or equal to (≤) 30% residual stenosis at the conclusion of the index procedure
Time frame: At the conclusion of the index procedure
Major amputation in patients with SMART CONTROL for obstructive iliac artery disease
Major amputation at 12 months post-index procedure
Time frame: At 12 months post-index procedure
Technical success of SMART CONTROL in patients with obstructive SFA disease
Technical success, defined as achievement of a final diameter stenosis of less than or equal to (≤) 30% residual stenosis at the conclusion of the index procedure
Time frame: At the conclusion of the index procedure
Major amputation in patients treated with SMART CONTROL for obstructive SFA disease
Major amputation at 12 months post-index procedure
Time frame: At 12 months post-index procedure
Technical success of SMART Flex in patients with obstructive SFA disease
Technical success, defined as achievement of a final diameter stenosis of less than or equal to (≤) 30% residual stenosis at the conclusion of the index procedure
Time frame: At the conclusion of the index procedure
Major amputation in patients treated with SMART Flex for obstructive SFA disease
Major amputation at 12 months post-index procedure
Time frame: At 12 months post-index procedure
Technical success of SMART Flex in patients with obstructive PPA disease
Technical success, defined as achievement of a final diameter stenosis of less than or equal to (≤) 30% residual stenosis at the conclusion of the index procedure
Time frame: At the conclusion of the index procedure
Major amputation in patients treated with SMART Flex for obstructive PPA disease
Major amputation at 12 months post-index procedure
Time frame: At 12 months post-index procedure
Patency at 12 months post-index procedure in patients treated with SMART 120/150 for obstructive SFA disease
Patency at 12 months post-index procedure, defined as achievement of less than or equal to (≤) 50% diameter stenosis
Time frame: At 12 months post-index procedure
Patency at 12 months post-index procedure in patients treated with SMART 120/150 for obstructive PPA disease
Patency at 12 months post-index procedure, defined as achievement of less than or equal to (≤) 50% diameter stenosis
Time frame: At 12 months post-index procedure
Patency at 12 months post-index procedure in patients treated with SMART CONTROL for obstructive iliac artery disease
Patency at 12 months post-index procedure, defined as achievement of less than or equal to (≤) 50% diameter stenosis
Time frame: At 12 months post-index procedure
Patency at 12 months post-index procedure in patients treated with SMART CONTROL for obstructive SFA disease
Patency at 12 months post-index procedure, defined as achievement of less than or equal to (≤) 50% diameter stenosis
Time frame: At 12 months post-index procedure
Patency at 12 months post-index procedure in patients treated with SMART Flex for obstructive SFA disease
Patency at 12 months post-index procedure, defined as achievement of less than or equal to (≤) 50% diameter stenosis
Time frame: At 12 months post-index procedure
Patency at 12 months post-index procedure in patients treated with SMART Flex for obstructive PPA disease
Patency at 12 months post-index procedure, defined as achievement of less than or equal to (≤) 50% diameter stenosis
Time frame: At 12 months post-index procedure
Target lesion restenosis in patients treated with SMART 120/150 for obstructive SFA disease
Target lesion restenosis, defined as greater than (\>) 50% diameter stenosis at 12 months post-index procedure
Time frame: At 12 months post-index procedure
Target lesion restenosis in patients treated with SMART 120/150 for obstructive PPA disease
Target lesion restenosis, defined as greater than (\>) 50% diameter stenosis at 12 months post-index procedure
Time frame: At 12 months post-index procedure
Target lesion restenosis in patients treated with SMART CONTROL for obstructive iliac artery disease
Target lesion restenosis, defined as greater than (\>) 50% diameter stenosis at 12 months post-index procedure
Time frame: At 12 months post-index procedure
Target lesion restenosis in patients treated with SMART CONTROL for obstructive SFA disease
Target lesion restenosis, defined as greater than (\>) 50% diameter stenosis at 12 months post-index procedure
Time frame: At 12 months post-index procedure
Target lesion restenosis in patients treated with SMART Flex for obstructive SFA disease
Target lesion restenosis, defined as greater than (\>) 50% diameter stenosis at 12 months post-index procedure
Time frame: At 12 months post-index procedure
Target lesion restenosis in patients treated with SMART Flex for obstructive PPA disease
Target lesion restenosis, defined as greater than (\>) 50% diameter stenosis at 12 months post-index procedure
Time frame: At 12 months post-index procedure
Procedural success in patients treated with SMART 120/150 for obstructive SFA disease
Procedural success, defined as successful stent deployment without occurrence of any procedural complications
Time frame: At the conclusion of the index procedure
Procedural success in patients treated with SMART 120/150 for obstructive PPA disease
Procedural success, defined as successful stent deployment without occurrence of any procedural complications
Time frame: At the conclusion of the index procedure
Procedural success in patients treated with SMART CONTROL for obstructive iliac artery disease
Procedural success, defined as successful stent deployment without occurrence of any procedural complications
Time frame: At the conclusion of the index procedure
Procedural success in patients treated with SMART CONTROL for obstructive SFA disease
Procedural success, defined as successful stent deployment without occurrence of any procedural complications
Time frame: At the conclusion of the index procedure
Procedural success in patients treated with SMART Flex for obstructive SFA disease
Procedural success, defined as successful stent deployment without occurrence of any procedural complications
Time frame: At the conclusion of the index procedure
Procedural success in patients treated with SMART Flex for obstructive PPA disease
Procedural success, defined as successful stent deployment without occurrence of any procedural complications
Time frame: At the conclusion of the index procedure
Target Lesion Revascularization in patients treated with SMART 120/150 for obstructive SFA disease
Target Lesion Revascularization through 12 months post-index procedure
Time frame: Through 12 months post-index procedure
Target Lesion Revascularization in patients treated with SMART 120/150 for obstructive PPA disease
Target Lesion Revascularization through 12 months post-index procedure
Time frame: Through 12 months post-index procedure
Target Lesion Revascularization in patients treated with SMART CONTROL for obstructive iliac artery disease
Target Lesion Revascularization through 12 months post-index procedure
Time frame: Through 12 months post-index procedure
Target Lesion Revascularization in patients treated with SMART CONTROL for obstructive SFA disease
Target Lesion Revascularization through 12 months post-index procedure
Time frame: Through 12 months post-index procedure
Target Lesion Revascularization in patients treated with SMART Flex for obstructive SFA disease
Target Lesion Revascularization through 12 months post-index procedure
Time frame: Through 12 months post-index procedure
Target Lesion Revascularization in patients treated with SMART Flex for obstructive PPA disease
Target Lesion Revascularization through 12 months post-index procedure
Time frame: Through 12 months post-index procedure
All-Cause Mortality through 30 days post-index procedure in patients treated with SMART 120/150 for obstructive SFA disease
All-Cause Mortality through 30 days post-index procedure
Time frame: Through 30 days post-index procedure
All-Cause Mortality through 30 days post-index procedure in patients treated with SMART 120/150 for obstructive PPA disease
All-Cause Mortality through 30 days post-index procedure
Time frame: Through 30 days post-index procedure
All-Cause Mortality through 30 days post-index procedure in patients treated with SMART CONTROL for obstructive iliac artery disease
All-Cause Mortality through 30 days post-index procedure
Time frame: Through 30 days post-index procedure
All-Cause Mortality through 30 days post-index procedure in patients treated with SMART CONTROL for obstructive SFA disease
All-Cause Mortality through 30 days post-index procedure
Time frame: Through 30 days post-index procedure
All-Cause Mortality through 30 days post-index procedure in patients treated with SMART Flex for obstructive SFA disease
All-Cause Mortality through 30 days post-index procedure
Time frame: Through 30 days post-index procedure
All-Cause Mortality through 30 days post-index procedure in patients treated with SMART Flex for obstructive PPA disease
All-Cause Mortality through 30 days post-index procedure
Time frame: Through 30 days post-index procedure
Rate of serious adverse events (SAE) through 36 months (3 years) post-index procedure in patients treated with SMART 120/150 for obstructive SFA disease
Rate of serious adverse events (SAE) through 36 months (3 years) post-index procedure
Time frame: Through 36 months (3 years) post-index procedure
Rate of serious adverse events (SAE) through 36 months (3 years) post-index procedure in patients treated with SMART 120/150 for obstructive PPA disease
Rate of serious adverse events (SAE) through 36 months (3 years) post-index procedure
Time frame: Through 36 months (3 years) post-index procedure
Rate of serious adverse events (SAE) through 36 months (3 years) post-index procedure in patients treated with SMART CONTROL for obstructive iliac artery disease
Rate of serious adverse events (SAE) through 36 months (3 years) post-index procedure
Time frame: Through 36 months (3 years) post-index procedure
Rate of serious adverse events (SAE) through 36 months (3 years) post-index procedure in patients treated with SMART CONTROL for obstructive SFA disease
Rate of serious adverse events (SAE) through 36 months (3 years) post-index procedure
Time frame: Through 36 months (3 years) post-index procedure
Rate of serious adverse events (SAE) through 36 months (3 years) post-index procedure in patients treated with SMART Flex for obstructive SFA disease
Rate of serious adverse events (SAE) through 36 months (3 years) post-index procedure
Time frame: Through 36 months (3 years) post-index procedure
Rate of serious adverse events (SAE) through 36 months (3 years) post-index procedure in patients treated with SMART Flex for obstructive PPA disease
Rate of serious adverse events (SAE) through 36 months (3 years) post-index procedure
Time frame: Through 36 months (3 years) post-index procedure
Rate of serious adverse events (SAE) through 60 months (5 years) post-index procedure in patients treated with SMART 120/150 for obstructive SFA disease
Rate of serious adverse events (SAE) through 60 months (5 years) post-index procedure
Time frame: Through 60 months (5 years) post-index procedure
Rate of serious adverse events (SAE) through 60 months (5 years) post-index procedure in patients treated with SMART 120/150 for obstructive PPA disease
Rate of serious adverse events (SAE) through 60 months (5 years) post-index procedure
Time frame: Through 60 months (5 years) post-index procedure
Rate of serious adverse events (SAE) through 60 months (5 years) post-index procedure in patients treated with SMART CONTROL for obstructive iliac artery disease
Rate of serious adverse events (SAE) through 60 months (5 years) post-index procedure
Time frame: Through 60 months (5 years) post-index procedure
Rate of serious adverse events (SAE) through 60 months (5 years) post-index procedure in patients treated with SMART CONTROL for obstructive SFA disease
Rate of serious adverse events (SAE) through 60 months (5 years) post-index procedure
Time frame: Through 60 months (5 years) post-index procedure
Rate of serious adverse events (SAE) through 60 months (5 years) post-index procedure in patients treated with SMART Flex for obstructive SFA disease
Rate of serious adverse events (SAE) through 60 months (5 years) post-index procedure
Time frame: Through 60 months (5 years) post-index procedure
Rate of serious adverse events (SAE) through 60 months (5 years) post-index procedure in patients treated with SMART Flex for obstructive PPA disease
Rate of serious adverse events (SAE) through 60 months (5 years) post-index procedure
Time frame: Through 60 months (5 years) post-index procedure
Rate of serious adverse device effects (SADE) through 36 months (3 years) post-index procedure in patients treated with SMART 120/150 for obstructive SFA disease
Rate of serious adverse device effects (SADE) through 36 months (3 years) post-index procedure
Time frame: Through 36 months (3 years) post-index procedure
Rate of serious adverse device effects (SADE) through 36 months (3 years) post-index procedure in patients treated with SMART 120/150 for obstructive PPA disease
Rate of serious adverse device effects (SADE) through 36 months (3 years) post-index procedure
Time frame: Through 36 months (3 years) post-index procedure
Rate of serious adverse device effects (SADE) through 36 months (3 years) post-index procedure in patients treated with SMART CONTROL for obstructive iliac artery disease
Rate of serious adverse device effects (SADE) through 36 months (3 years) post-index procedure
Time frame: Through 36 months (3 years) post-index procedure
Rate of serious adverse device effects (SADE) through 36 months (3 years) post-index procedure in patients treated with SMART CONTROL for obstructive SFA disease
Rate of serious adverse device effects (SADE) through 36 months (3 years) post-index procedure
Time frame: Through 36 months (3 years) post-index procedure
Rate of serious adverse device effects (SADE) through 36 months (3 years) post-index procedure in patients treated with SMART Flex for obstructive SFA disease
Rate of serious adverse device effects (SADE) through 36 months (3 years) post-index procedure
Time frame: Through 36 months (3 years) post-index procedure
Rate of serious adverse device effects (SADE) through 36 months (3 years) post-index procedure in patients treated with SMART Flex for obstructive PPA disease
Rate of serious adverse device effects (SADE) through 36 months (3 years) post-index procedure
Time frame: Through 36 months (3 years) post-index procedure
Rate of serious adverse device effects (SADE) through 60 months (5 years) post-index procedure in patients treated with SMART 120/150 for obstructive SFA disease
Rate of serious adverse device effects (SADE) through 60 months (5 years) post-index procedure
Time frame: Through 60 months (5 years) post-index procedure
Rate of serious adverse device effects (SADE) through 60 months (5 years) post-index procedure in patients treated with SMART 120/150 for obstructive PPA disease
Rate of serious adverse device effects (SADE) through 60 months (5 years) post-index procedure
Time frame: Through 60 months (5 years) post-index procedure
Rate of serious adverse device effects (SADE) through 60 months (5 years) post-index procedure in patients treated with SMART CONTROL for obstructive iliac artery disease
Rate of serious adverse device effects (SADE) through 60 months (5 years) post-index procedure
Time frame: Through 60 months (5 years) post-index procedure
Rate of serious adverse device effects (SADE) through 60 months (5 years) post-index procedure in patients treated with SMART CONTROL for obstructive SFA disease
Rate of serious adverse device effects (SADE) through 60 months (5 years) post-index procedure
Time frame: Through 60 months (5 years) post-index procedure
Rate of serious adverse device effects (SADE) through 60 months (5 years) post-index procedure in patients treated with SMART Flex for obstructive SFA disease
Rate of serious adverse device effects (SADE) through 60 months (5 years) post-index procedure
Time frame: Through 60 months (5 years) post-index procedure
Rate of serious adverse device effects (SADE) through 60 months (5 years) post-index procedure in patients treated with SMART Flex for obstructive PPA disease
Rate of serious adverse device effects (SADE) through 60 months (5 years) post-index procedure
Time frame: Through 60 months (5 years) post-index procedure
Rate of stent fractures by type at 6 months post-index procedure in patients treated with SMART 120/150 for obstructive SFA disease
Rate of stent fractures at 6 months post-index procedure
Time frame: At 6 months post-index procedure
Rate of stent fractures by type at 6 months post-index procedure in patients treated with SMART 120/150 for obstructive PPA disease
Rate of stent fractures at 6 months post-index procedure
Time frame: At 6 months post-index procedure
Rate of stent fractures by type at 6 months post-index procedure in patients treated with SMART CONTROL for obstructive iliac artery disease
Rate of stent fractures at 6 months post-index procedure
Time frame: At 6 months post-index procedure
Rate of stent fractures by type at 6 months post-index procedure in patients treated with SMART CONTROL for obstructive SFA disease
Rate of stent fractures at 6 months post-index procedure
Time frame: At 6 months post-index procedure
Rate of stent fractures at 6 months by type post-index procedure in patients treated with SMART Flex for obstructive SFA disease
Rate of stent fractures at 6 months post-index procedure
Time frame: At 6 months post-index procedure
Rate of stent fractures at 6 months by type post-index procedure in patients treated with SMART Flex for obstructive PPA disease
Rate of stent fractures at 6 months post-index procedure
Time frame: At 6 months post-index procedure
Rate of stent fractures at 12 months by type post-index procedure in patients treated with SMART 120/150 for obstructive SFA disease
Rate of stent fractures at 12 months post-index procedure
Time frame: At 12 months post-index procedure
Rate of stent fractures at 12 months by type post-index procedure in patients treated with SMART 120/150 for obstructive PPA disease
Rate of stent fractures at 12 months post-index procedure
Time frame: At 12 months post-index procedure
Rate of stent fractures at 12 months by type post-index procedure in patients treated with SMART CONTROL for obstructive iliac artery disease
Rate of stent fractures at 12 months post-index procedure
Time frame: At 12 months post-index procedure
Rate of stent fractures at 12 months by type post-index procedure in patients treated with SMART CONTROL for obstructive SFA disease
Rate of stent fractures at 12 months post-index procedure
Time frame: At 12 months post-index procedure
Rate of stent fractures at 12 months by type post-index procedure in patients treated with SMART Flex for obstructive SFA disease
Rate of stent fractures at 12 months post-index procedure
Time frame: At 12 months post-index procedure
Rate of stent fractures at 12 months by type post-index procedure in patients treated with SMART Flex for obstructive PPA disease
Rate of stent fractures at 12 months post-index procedure
Time frame: At 12 months post-index procedure
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Jan 2026; primary completion for May 2026, 3 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.